Hospitals Worry HRSA’s Latest 340B RFI Aims To Avoid Legal Risks, Not Address Concerns

Why It Matters

The decision will dictate whether hospitals can preserve 340B savings for uncompensated care and will shape the legal and regulatory framework for drug‑pricing reforms across the health system.

Key Takeaways

• HRSA issued a new 340B RFI focusing on legal risk mitigation.
• Pilot aims to replace discounts with a rebate model under OMB review.
• Hospital trade group says safeguards are missing, could strain hospitals.
• Shift could reshape drug pricing and compliance for thousands of providers.

Pulse Analysis

The 340B program, created in 1992, allows eligible hospitals and clinics to purchase outpatient drugs at steep discounts, generating revenue that subsidizes care for uninsured and low‑income patients. Over the past decade, the program has faced increasing scrutiny from manufacturers and policymakers who argue it inflates drug prices and lacks transparency. HRSA, the federal agency that oversees 340B, has responded with a series of requests for information aimed at modernizing the model, most recently proposing a pilot that would replace the discount mechanism with a rebate structure tied to actual drug utilization.

The latest RFI emphasizes legal risk avoidance, signaling HRSA’s intent to pre‑empt litigation that has plagued the program for years. By shifting to a rebate model, the agency hopes to create a more defensible framework that aligns with recent court rulings. However, the Hospital Association of America’s 340B coalition warns that the proposal omits critical safeguards—such as clear eligibility criteria and audit protocols—necessary to prevent hospitals from shouldering unexpected costs. Their concern is that without these protections, the rebate system could erode the financial buffer that 340B provides, especially for safety‑net hospitals serving vulnerable populations.

If the OMB approves the pilot, the ripple effects could be profound. A successful rebate model might set a new national standard, prompting manufacturers to renegotiate pricing contracts and potentially reshaping the broader drug‑pricing landscape. Conversely, a failed pilot could trigger legislative backlash, prompting Congress to intervene with stricter oversight or even repeal provisions of the 340B statute. Hospitals are therefore monitoring the process closely, preparing contingency plans, and lobbying for amendments that preserve the program’s core mission while addressing legitimate legal concerns. The outcome will be a bellwether for how federal health policy balances cost containment with access to essential medicines.